A Chinese OTC Drugmaker Gets a FDA Warning Letter

| By | Contamination control, FDA
0
147

The FDA posted a warning letter this week for Huaian Zongheng Bio-Tech for its plant in Huaian, China, which it says makes over-the-counter drug products, many of them for children. It says the company ships them to the U.S. without testing ingredients or retained samples of the finished products to see if they meet specs.

The company’s products were also put import alert in November.

The FDA was particularly concerned over the fact that the company uses glycerin in some of its products, pointing out that the use of “glycerin contaminated with diethylene glycol (DEG) has resulted in various lethal poisoning incidents in humans worldwide.”

The company was ordered to rely on FDA guidance for use of the ingredient.

The FDA was concerned enough about the products of Huaian Zongheng Bio-Tech that it recommended it get a third-party consultant to help it meet FDA manufacturing standards.

VIAfierce pharma
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.